Pharmala Biotech (MDMA) investor relations material

Leadership and company overview

• CEO Nick Kadysh described his background in healthcare policy and regulatory affairs, leading to the founding of the company focused on MDMA drug development and supply.

• The company has maintained its original dual focus: developing novel MDMA-like drugs and being the leading supplier of clinical-grade MDMA globally.

• Supplies MDMA to over 35 clinical trials worldwide, including major institutions and the U.S. military, with a significant presence in Australia and New Zealand.

• Emphasizes operational focus and capital efficiency, having grown with minimal external funding.

Competitive positioning and customer relationships

• Maintains a legal supply moat for MDMA, with about 30% of clinical trial customers placing repeat orders, indicating strong customer loyalty.

• Reliability, regulatory compliance, and manufacturing quality are key factors for customer retention, especially as MDMA moves toward commercial use.

• Expansion in Australia and New Zealand, with expectations for U.S. regulatory progress, is driven by the company's role in building scientific evidence for MDMA.

Data-driven business model and partnerships

• Frequently supplies MDMA at low or no cost in exchange for full access to clinical trial data, focusing on both safety and efficacy outcomes.

• Carefully evaluates the scientific and commercial value of each data-sharing arrangement, prioritizing novel indications.

• Holds perpetual, non-exclusive licenses to full datasets, using them for regulatory, commercial, or partnership purposes, while respecting researchers' publication rights.